Thu, May 3, 2018
Wed, May 2, 2018
Tue, May 1, 2018
Mon, April 30, 2018
Fri, April 27, 2018
Thu, April 26, 2018
Wed, April 25, 2018
Tue, April 24, 2018
Mon, April 23, 2018

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $207 on, Apr 27th, 2018


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-207-on-apr-27th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $200 to $207 on, Apr 27th, 2018.

Matthew has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $200 on, Monday, March 5th, 2018
  • Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $211 on, Tuesday, February 13th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $196 on, Tuesday, February 13th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $191 on, Thursday, February 1st, 2018
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $200 on, Thursday, February 1st, 2018
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $197 on, Thursday, February 1st, 2018

Publication Contributing Sources